Show simple item record

dc.contributor.authorHaggag, Y.
dc.contributor.authorAbu Ras, Bayan
dc.contributor.authorEl-Tanani, Yahia
dc.contributor.authorTambuwala, M.M.
dc.contributor.authorMcCarron, P.
dc.contributor.authorIsreb, Mohammad
dc.contributor.authorEl-Tanani, Mohamed
dc.date.accessioned2020-08-26T10:48:33Z
dc.date.accessioned2020-09-24T13:56:49Z
dc.date.available2020-08-26T10:48:33Z
dc.date.available2020-09-24T13:56:49Z
dc.date.issued2020-11
dc.identifier.citationHaggag Y, Abu Ras B, El-Tanani Y et al (2020) Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells. Expert Opinion on Drug Delivery. 17(11): 1655-1669.en_US
dc.identifier.urihttp://hdl.handle.net/10454/18020
dc.descriptionYesen_US
dc.description.abstractMultidrug resistance (MDR) limits the beneficial outcomes of conventional breast cancer chemotherapy. Ras-related nuclear protein (Ran-GTP) plays a key role in these resistance mechanisms, assisting cancer cells to repair damage to DNA. Herein, we investigate the co-delivery of Ran-RCC1 inhibitory peptide (RAN-IP) and doxorubicin (DOX) to breast cancer cells using liposomal nanocarriers. A liposomal delivery system, co-encapsulating DOX, and RAN-IP, was prepared using a thin-film rehydration technique. Dual-loaded liposomes were optimized by systematic modification of formulation variables. Real-Time-Polymerase Chain Reaction was used to determine Ran-GTP mRNA expression. In vitro cell lines were used to evaluate the effect of loaded liposomes on the viability of breast and lung cancer cell lines. In vivo testing was performed on a murine Solid Ehrlich Carcinoma model. RAN-IP reversed the Ran-expression-mediated MDR by inhibiting the Ran DNA damage repair function. Co-administration of RAN-IP enhanced sensitivity of DOX in breast cancer cell lines. Finally, liposome-mediated co-delivery with RAN-IP improved the anti-tumor effect of DOX in tumor-bearing mice when compared to single therapy. This study is the first to show the simultaneous delivery of RAN-IP and DOX using liposomes can be synergistic with DOX and lead to tumor regression in vitro and in vivo.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.1080/17425247.2020.1813714en_US
dc.rights© 2020 Taylor & Francis. This is an Author's Original Manuscript of an article published by Taylor & Francis in Expert Opinion on Drug Delivery on 15 Sep 2020 available online at https://doi.org/10.1080/17425247.2020.1813714.
dc.subjectDoxorubicinen_US
dc.subjectRan-inhibitory peptideen_US
dc.subjectDrug deliveryen_US
dc.subjectLiposomeen_US
dc.subjectFormulationen_US
dc.subjectOptimisationen_US
dc.subjectBreast canceren_US
dc.titleCo-delivery of a RanGTP inhibitory peptide and doxorubicin using dual loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cellsen_US
dc.status.refereedYesen_US
dc.date.Accepted2020-08-19
dc.date.application2020-08-25
dc.typeArticleen_US
dc.type.versionAccepted manuscripten_US
dc.date.updated2020-08-26T09:48:38Z
refterms.dateFOA2020-09-24T14:32:53Z


Item file(s)

Thumbnail
Name:
haggag_et_al_2020.pdf
Size:
495.6Kb
Format:
PDF
Thumbnail
Name:
EODD-final.docx
Size:
416.2Kb
Format:
Microsoft Word 2007

This item appears in the following Collection(s)

Show simple item record